Anti-Paxillin (phospho Y118) antibody [EPR1903]

• WB

Unknown

Western blot - Anti-Paxillin (phospho Y118) antibody [EPR1903] (AB109547)

Blocking and dilution buffer : 5% NFDM/TBST.

All lanes:

Western blot - Anti-Paxillin (phospho Y118) antibody [EPR1903] (ab109547) at 1/1000 dilution

Lane 1:

Jurkat (human T cell leukemia T lymphocyte) whole cell lysate at 10 µg

Lane 2:

Jurkat treated with 50mM pervanadate for 5 min whole cell lysate at 10 µg

Lane 3:

Jurkat treated with 50mM pervanadate for 5 min whole cell lysate, then the membrane was incubated with alkaline phosphatase at 10 µg

Secondary

All lanes:

Western blot - Goat Anti-Rabbit IgG H&L (HRP) (<a href='/en-us/products/secondary-antibodies/goat-rabbit-igg-h-l-hrp-ab97051'>ab97051</a>) at 1/20000 dilution

Predicted band size: 65 kDa

Observed band size: 65 kDa

false

• WB

Unknown

Western blot - Anti-Paxillin (phospho Y118) antibody [EPR1903] (AB109547)

All lanes:

Western blot - Anti-Paxillin (phospho Y118) antibody [EPR1903] (ab109547) at 1/1000 dilution

Lane 1:

HeLa cell lysate at 10 µg

Lane 2:

HeLa cell lysate treated with pervanadate at 10 µg

Predicted band size: 46 kDa,65 kDa

false

• Dot

Unknown

Dot Blot - Anti-Paxillin (phospho Y118) antibody [EPR1903] (AB109547)

Dot blot analysis of Paxillin (phospho Y118) phospho peptide (Lane 1) and Paxillin phospho peptide (Lane 2) labelling Paxillin (phospho Y118) with ab109547 at a dilution of 1/1000. A Goat Anti-Rabbit IgG (H+L) Peroxidase conjugated (ab97051) was used as the secondary antibody at a dilution of 1/20000. Blocking buffer : 5% NFDM/BST. Dilution buffer : 5% NFDM /TBST.

• WB

CiteAb

Western blot - Anti-Paxillin (phospho Y118) antibody [EPR1903] (AB109547)

Western Blotting using Anti-Paxillin (phospho Y118) antibody [EPR1903], ab109547. Publication image from Liu, S. C. et al., 2018, Nat Commun, 30504771. Legend direct from paper.

LIFR–YAP1 signaling is critical for LIF-mediated invasion of NPC cells. a Endogenous protein expression of LIFR, p-YAP1(S127), and YAP1 in three cancer cell lines. b Immunostaining for YAP1 and LIFR in three cancer cell lines. Scale bars, 10 µm. c Western blot analysis of LIFR and p-YAP1 (S127) protein levels in WT and cLIF cancer cells transfected with SMARTpool LIFR siRNA or control siRNA. The p-YAP1 (S127) expressions with respect to total YAP1 levels were quantified and presented as mean ± SEM (n = 3). At least three independent experiments were performed. d Western blot analysis of expression of focal adhesion molecules and SRC in WT and LIF+/− cancer cells transfected with YAP1 siRNA. GAPDH was used as the loading control. e Representative images for p-PXN (Y118) expression in WT or LIF+/− cancer cells transfected with YAP1 or control siRNA (n = 3). Alexa Fluor 488 phalloidin (green) was used to stain F-actin. Scale bars, 10 µm. f Representative images of the HUVEC layer replacement assay. Fixed numbers of WT or LIF+/− cancer cells transfected with YAP1 or control siRNA were plated onto the confluent HUVEC layer and co-cultivated for 24 h. Cancer cells were labeled with antibody against pan-cytokeratin (red) and HUVEC cells with antibody against VE-cadherin (green). Scale bars, 20 µm. g, h Quantification of displaced areas depicted in f. WT cancer cells (g). LIF+/− cancer cells (h). Invaded areas were calculated using CellSens imaging software (Olympus). Data are presented with scatter dot plot (mean ± SEM). Each black dot represents one captured image. Mann–Whitney test. i Immunohistochemistry for LIFR and YAP1 expression (brown) in consecutive NPC biopsy sections derived from primary or bone marrow metastatic lesions

false

• WB

CiteAb

Western blot - Anti-Paxillin (phospho Y118) antibody [EPR1903] (AB109547)

Western Blotting using Anti-Paxillin (phospho Y118) antibody [EPR1903], ab109547. Publication image from Liu, S. C. et al., 2018, Nat Commun, 30504771. Legend direct from paper.

LIF regulates focal adhesion molecules. a Detection of endogenous focal adhesion kinases in cancer cells via western blot using GAPDH as a loading control. b LIF regulates the spatial distribution of activated focal adhesion kinases. Cells were labeled with antibodies against phospho-PXN (Y118) or phospho-FAK (Y397). Alexa Fluor 488 phalloidin (green) was used to stain F-actin. Blue, nuclear staining. Scale bars, 10 µm. c Live imaging of focal adhesion during transendothelial invasion. Cancer cells expressing LifeAct-RFP were pre-labeled with Talin-GFP and plated onto the HUVEC layer. Images were captured 24 h post-plating. Blue, nuclei labeled with Hoechst33342. Scale bars, 20 µm. The white arrow indicates the damaged area caused by Talin-rich elongated protrusion. d Representative images of LIF, p-PXN (Y118), and p-FAK (Y397) expression in paraffin-embedded consecutive NPC tissue sections. Scale bars, 50 µm. e, f Correlation analyses based on IHC scores (Spearman’s correlation test). Correlations were evident between LIF and p-FAK (Y397) (e) and LIF and p-PXN (Y118) (f)

false

• WB

CiteAb

Western blot - Anti-Paxillin (phospho Y118) antibody [EPR1903] (AB109547)

Western Blotting using Anti-Paxillin (phospho Y118) antibody [EPR1903], ab109547. Publication image from Liu, S. C. et al., 2018, Nat Commun, 30504771. Legend direct from paper.

AZD0530 treatment suppresses LIF-mediated tumor invasion. a Western blot analysis of YAP1 and focal adhesion proteins in cancer cells treated with AZD0530 (5 µM). Protein lysates were harvested at 24 h post treatment. b Immunostaining for YAP1 (red) in cancer cells treated with AZD0530. Alexa Fluor 488 phalloidin (green) was used to stain F-actin. Blue, nuclear staining. Scale bars, 10 µm. c–e Representative images of YAP1 (c), p-PXN (Y118) (d), and p-FAK (Y397) (e) expression in mouse WT and cLIF xenografts treated with AZD0530 or vehicle. Scale bars, 50 µm. f Quantification of mouse NPC xenografts with events of local invasion based on results of hematoxylin and eosin staining. The AZD0530 treatment procedure in the mouse model is described in Methods

false